|
May 9
|
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
|
|
May 9
|
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
|
|
May 7
|
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
|
|
May 7
|
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
|
|
Mar 28
|
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
|
|
Mar 25
|
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
|
|
Mar 21
|
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
|
|
Jan 4
|
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
|
|
Dec 4
|
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 29
|
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
|
|
Nov 9
|
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
|
|
Nov 8
|
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
|
|
Nov 2
|
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
|